Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sato to Enhance Main Brands, Promote Strategic Alliances
February 7, 2005
- 1st 3 Qtrs Business Results
February 7, 2005
- OTC NEWS IN BRIEF
February 7, 2005
- NEW PRODUCTS
February 7, 2005
- 1st 3 Qtrs Business Results
February 7, 2005
- Oxaliplatin Recommended for Approval
February 7, 2005
- MEDICAL DEVICE NEWS IN BRIEF
February 7, 2005
- Use of 3 Unapproved Drugs to Be Allowed under New Framework
February 7, 2005
- DIAGNOSTIC NEWS IN BRIEF
February 7, 2005
- Sosei, Abgenix Jointly Identify Lead Antibodies
February 7, 2005
- Mochida to Beef Up Split-off Houses
February 7, 2005
- Thalidomide Given Orphan Status
February 7, 2005
- Ryukinkyo's Model Contracts Need Revisions: EAD Director
February 7, 2005
- Insurance Rate to Differ in Each Pref.: Proposal
February 7, 2005
- REGULATORY NEWS IN BRIEF
February 7, 2005
- Aiming at an Over 4% Market Share by 2007: Mr Baba of Novartis
February 7, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 7, 2005
- BULLETIN
February 7, 2005
- AnGes MG to Jointly Research on Gene Therapy with Univ. of Tokyo Hospital
February 7, 2005
- Nakakita to Consolidate Its Position as Regional Wholesaler
February 7, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…